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Early uptake of [11C]-Pittsburgh Compound B (ePiB, 0e6 minutes) estimates cerebral blood ﬂow. We
studied ePiB in 13 PiB-negative and 10 PiB-positive subjects with mild cognitive impairment (MCI,
n ¼ 23) and 11 PiB-positive and 74 PiB-negative cognitively healthy elderly control subjects (HCS, n ¼ 85)
in 6 bilateral volumes of interest: posterior cingulate cortex (PCC), hippocampus (hipp), temporoparietal
region, superior parietal gyrus, parahippocampal gyrus (parahipp), and inferior frontal gyrus (IFG) for the
associations with cognitive status, age, amyloid deposition, and apolipoprotein E ε4-allele. We observed
no difference in ePiB between PiB-positive and -negative subjects and carriers and noncarriers. EPiB
decreased with age in PiB-positive subjects in bilateral superior parietal gyrus, bilateral temporoparietal
region, right IFG, right PCC, and left parahippocampal gyrus but not in PiB-negative subjects. MCI had
lower ePiB than HCS (left PCC, left IFG, and left and right hipp). Lowest ePiB values were found in MCI of
70 years and older, who also displayed high cortical PiB binding. This suggests that lowered regional
cerebral blood ﬂow indicated by ePiB is associated with age in the presence but not in the absence of
amyloid pathology.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction impairment (MCI) because of AD, amyloid PET with the [11C]-Pitts-1.1. The potential of [11C]-Pittsburgh Compound B as a dual
biomarker
In the recommendations from the National Institute on Aging-
Alzheimer’s Associationworkgroups on the diagnostic guidelines for
identifying preclinical Alzheimer’s disease (AD) or mild cognitiveesearch and Psychogeriatric
ren, Switzerland. Tel.: þ41 44
Inc. This is an open access article uburgh Compound B (PiB) is considered to be a marker of cerebral
amyloid deposition, whereas a reduction in temporoparietal glucose
metabolism assessed by [18F] ﬂuorodeoxyglucose-positron emission
tomography (FDG-PET) is considered a marker of downstream
neuronal injury (Albert et al., 2011; Sperling et al., 2011). The same
criteria imply that the combination of markers for amyloid deposi-
tion, neuronal injury, and synaptic dysfunction is important for the
prognosis in MCI and preclinical AD. However, a combination of
amyloid- and FDG-PET may not always be feasible because of the
higher cost, associated patient discomfort, and radioactive dose
burden. In this context, dynamic PETwith PiBmay be able to provide
information on regional cerebral blood ﬂow (rCBF) in addition to thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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constant K1 for PiB uptake and tracer extraction, which is directly
related to CBF,was investigated as an estimate for cortical bloodﬂow.
In a rhesus monkey, the regional distributions of K1 and CBF were
similar, and changes in K1 were found to closely follow changes in
CBF as measured by H215O PET after increasing the level of CO2 in the
blood (Blomquist et al., 2008). The same study found that PiB K1was
lower in subjects with AD compared with HCS, indicative of lower
CBF in AD subjects. Although the exact mechanisms are still under
debate, CBF and cerebral glucose metabolism are tightly coupled
(Paulson et al., 2010). The correlation between initial PiB uptake in
dynamic PET as an estimate of K1 and cerebral glucose metabolism
assessedwith FDG-PETwas studied in a large cohort of subjectswith
frontotemporal lobedementia andAD(Rostomianet al., 2011). A time
frame for early PiB uptake (1e8minutes) exhibited a high correlation
with FDG uptake and resulted in a comparable diagnostic value for
discriminating between AD and frontotemporal lobe dementia.
Furthermore, a strong correlation between FDG-PET and early PiB
signal using theﬁrst 6minutes of a dynamic PiB-PETscanwas shown
(Forsberg et al., 2012). When AD, MCI, and HCS were pooled and
stratiﬁed into PiB-positive and -negative subjects, PiB-positive (i.e.,
high cortical amyloid load) subjects exhibited lower cerebral glucose
metabolism and reduced early uptake of PiB (ePiB) indicating
reduced CBF. Correspondingly, relative tracer delivery derived from a
simpliﬁed reference tissue model has also been demonstrated to be
positively correlated with the performance in the Mini-Mental State
Examination (Meyer et al., 2011) in brain regions including the
bilateral posterior cingulate cortex (PCC)/precuneus, lateral inferior
temporal cortex, and temporoparietal junction.
We hypothesized that ePiB, estimating changes in CBF and being
correlated with FDG-PET information, would be reduced in patients
with MCI compared with healthy elderly control subjects (HCS). We
used a maximum probability atlas (Gousias et al., 2008; Hammers
et al., 2003) to measure ePiB and amyloid load (PiB uptake be-
tween 50 and 70 minutes after tracer injection) in predeﬁned vol-
umes of interest (VOIs). These VOIs cover brain structures with
reduced FDG-PET signal described in a recent meta-analysis to be
predictive for short-term conversion from MCI to AD (Zhang et al.,
2012), namely the temporoparietal cortices (Anchisi et al., 2005;
Arnaiz et al., 2001; Chetelat et al., 2003; Drzezga et al., 2005;
Landau et al., 2010; Mosconi et al., 2004), PCC (Anchisi et al.,
2005; Drzezga et al., 2005; Landau et al., 2010; Nobili et al.,
2008), lateral frontal cortex (Nobili et al., 2008), and medi-
otemporal structures (Anchisi et al., 2005).
1.2. Risk factors of AD and CBF
The aggregation of protein structures (beta-amyloid and tau) is
considered as a central feature and an early event in the patho-
genesis of AD (Hardy and Higgins, 1992; Jack et al., 2013) that may
start decades before the onset of cognitive impairment (Braak et al.,
2011; Villemagne et al., 2013) and may affect brain integrity early
(Schreiner et al., 2014; Sperling et al., 2009; Steininger et al., 2014).
At the time cognitive symptoms become overt, a large number of
synaptic connections has already been lost (Arendt, 2009; Scheff
et al., 2011), and neurodegeneration can be observed (Mufson
et al., 2000). Hypometabolism and also reductions in CBF have
been considered to reﬂect synaptic loss (Giovacchini et al., 2011;
Herholz, 2011) and in a broader context neuronal injury. In the
hypothesis of the amyloid cascade and in a recently formulated
hypothetical biomarker model, they were put downstream to
amyloid and tau deposition (Jack et al., 2010). However, studies
in subjects at risk of AD, for example, young ApoE4 carriers
(Reiman et al., 2004; Scarmeas et al., 2003; Wierenga et al., 2013)
or subjects with a family history of AD (Mosconi et al., 2014), haverevealed alterations in glucose metabolism and CBF. Thus, a very
early and causative effect might be possible. Few studies on CBF or
regional glucose metabolism had also information on amyloid
deposition and apolipoprotein E (ApoE) genotype. Lower CBF was
identiﬁed by arterial spin labeling (ASL) in PiB-positive late MCI and
AD (Mattsson et al., 2014). Lower FDG-PET signal indicated hypo-
metabolism in cognitively normal apolipoprotein E ε4-allele car-
riers (ApoE4-carriers) compared with noncarriers (Knopman et al.,
2014) or in subjects with higher versus lower amyloid load
(Knopman et al., 2014; Lowe et al., 2014). In our study, we took
advantage of ePiB to study rCBF in addition to cerebral amyloid
deposition and ApoE genotype, in subjects who cover a spectrum of
cognitively healthy aging and MCI. We addressed potential effects
of age, ApoE genotype (ApoE4 carrier vs. noncarrier), and amyloid
deposition on rCBF estimated by ePiB.
2. Methods
2.1. Participants
Atotal of 25 subjectswithMCI and93 cognitivelyHCSunderwent
PET imaging with PiB. Subjects participated in 2 ongoing longitu-
dinal studies and were recruited through regular referrals to the
institution’s memory clinic, advertisement, and from a preexisting
longitudinal cohort. The 93 HCS were recruited from the study
“ImagingBrainBeta-Amyloid inAsymptomatic ElderlySubjects.” For
inclusion, subjects had to be aged between 55 and 80 years. Cogni-
tive health was ascertained by a Mini-Mental State Examination
(MMSE) score of27 and clinical examination that included clinical
workup and neuropsychological testing (see also Riese et al., 2015;
Steininger et al., 2014). Exclusion criteria were as follows: signiﬁ-
cant medication or drug abuse that may affect cognition, magnetic
resonance imaging (MRI) exclusion criteria, contraindications
against venipuncture, clinically relevant changes in red blood cell
count, allergy to PiB or any of its constituents, history of severe
allergic reactions to drugs or allergens, critical ormedically unstable
illness, pregnancy or lactation, and signiﬁcant exposure to radiation.
The 25 MCI subjects represent a subgroup from the study “The
Conversion of Mild Cognitive Impairment to Alzheimer’s Disease.”
MCIwas diagnosed according to the standard criteria (Winblad et al.,
2004) after a comprehensive clinical and neuropsychological
workup. Subjects had to be of age 60. Exclusion criteria were as
follows: clinically signiﬁcant neurologic, psychiatric, or internal
disease or medication or drug abuse that may affect cognition;
clinically signiﬁcant depression; MRI scans with the evidence of
infection, infarction, or other focal lesions; multiple lacunes or
lacunes in a critical memory structure; MRI exclusion criteria; con-
traindications against venipuncture; clinically relevant changes in
red blood cell count; exclusion criteria for PiB-PET (as mentioned
earlier); and critical or medically unstable illness. Both studies were
approved by the cantonal ethics committee of canton Zurich,
Switzerland. Subjectswereonlyaccepted afterproviding thewritten
informed consent.
2.2. PiB synthesis
Carbon-11 was produced via the 14N(p,a)11C nuclear reaction in
an on-site cyclotron (16.5 MeV, GE) in the form of [11C]-CO2. [11C]-
Methyl iodide ([11C]-CH3I) was generated in a 2-step reaction
sequence involving the catalytic reduction of [11C]CO2 to [11C]
methane and subsequent gas-phase iodination. After passing
through an AgOTf/C column at 190 C, the more reactive
[11C]-methyl triﬂate was formed. PiB was prepared based on the
published radiolabeling procedure in a 1-step reaction by reacting
the free amine precursor 6-HO-BTA-0 with [11C]-methyl triﬂate
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99% radiochemical purity after semiehigh-performance liquid
chromatography puriﬁcation. The total radiolabeling time was
around 40 minutes after the end of bombardment. Speciﬁc activity
was high and ranged from 80 to 320 GBq/mmoL at the end of the
synthesis. The radiochemical yield was 20%e30% (decay corrected).
PiB was formulated in saline with <10% ethanol for intravenous
injection, and pH was adjusted to 5e6.
2.3. PET acquisition
PET acquisition has been published before (Riese et al., 2015;
Steininger et al., 2014). An antecubital venous line was positioned
for theapplicationof approximately350MBqofPiB.DynamicPETdata
were acquired for 70minutes (415, 8 30, 9 60, 2180, and 10
300 seconds). If dynamic scanning was not feasible (e.g., participant
incapable of lying still>70minutes and limited scanneravailability), a
static image covering 50e70 minutes after tracer injection was ac-
quired for the assessment of cerebral amyloid deposition.
2.4. MR acquisition
MCI subjects were scanned on a 1.5-T Phillips Achieva with a
sequence repetition time 8.1 ms, echo time 3.7 ms, and 8 ﬂip angle,
and ﬁeld of view for the 160 sagittal slices with 1-mm single-slice
thickness was 240 mm anterior-posterior (AP), 240 mm foot to
head (FH), and 160mm right-left (RL). HCS subjectswere scanned on
a 3-T Phillips Achievawith a repetition time 8.2ms, echo time 3.7ms,
and 8 ﬂip angle, and ﬁeld of view for the 220 axial slices with 1-mm
single-slice thickness was 240 mm (AP), 220 mm (FH), and 188 mm
(RL). Nine MCI subjects were imaged on both the scanners to study a
potential effect of scanner on image analysis as MRI is used for cor-
egistration and gray-matter (GM) segmentation. Higher ePiB signal
(95% conﬁdence interval [CI] ofmean difference not including 0)was
observed via the 1.5-T image (MCI)ebased analysis pipeline in the
right inferior frontal gyrus (IFG), right PCC, right and left hippo-
campus (hipp), bilateral superior parietal gyrus (SPG), and bilateral
temporoparietal region (TR) (Supplementary Table 1).
2.5. Image analyses
All image processing was performed using the PMOD PNEURO
tool, version 3.4 (PMOD Ltd, Zurich, Switzerland). Frames 1e13
were averaged to aid coregistration with the subject’s
3-dimensional T1-weighted MR image using a normalized mutual-
informationebased registration. After normalization, a maximum
probability atlas (Hammers N30R83) was used to deﬁne VOIs based
on the segmentation of GM and white matter. Segmentation was
performed on the individual MRI (50% GM probability). The con-
struction of the N30R83 atlas and the segmentation algorithm have
been described elsewhere (Gousias et al., 2008; Hammers et al.,
2003). The combined transformation matrices (PET to MR and MR
to Montreal Neurologic Institute [MNI] space) were applied to the
dynamic PET images to perform all further analyses in the MNI
space. The average tracer uptake between 0e6 and 50e70 minutes
was calculated from the time-activity curves of the segmented GM
VOIs using SAS (version 9.3; SAS Institute Inc, Cary, NC, USA).
2.6. Calculation of cortical PiB retention and deﬁnition of PiB
status cutoff
Mean PiB uptake in all cortical VOIs (excluding occipital lobe,
insula, primary motor and sensorimotor cortices) and cerebellar
regionswas calculated from frames 50e70minutes using a volume-
weighted averaging procedure for derivation of global cortical andcerebellar PiB uptake, and the cortical-to-cerebellar standardized
uptake value ratio was calculated (henceforth “cortical PiB reten-
tion” or “PiB retention”). A numerical cutoff to deﬁne PiB-positive
status was calculated from the entire HCS cohort (n ¼ 93) accord-
ing to a previously described method (Vandenberghe et al., 2010).
The resulting cutoff was 1.265.2.7. Calculation of ePiB signal
Average uptake from the ﬁrst 13 PET frames (0e6 minutes) was
standardized by dividing the signal in the respective VOI by the
cerebellar mean for the ﬁrst 0e6minutes. Regions analyzed for ePiB
were single VOIs of the Hammers N30R83: left and right IFG, PCC,
hipp, parahippocampal gyrus (parahipp) (including ambient gyrus),
SPG, and a volume-weighted averaged group consisting of posterior
temporal lobe and inferolateral remainder of parietal lobe hence-
forth referred to as the TR. Frames 0e6 minutes were selected as
they have been shown to correlate with K1 and cerebral glucose
metabolism (Forsberg et al., 2012).2.8. ApoE genotyping
ApoE genotyping was performed by the restriction isotyping as
previously described (Hixson and Vernier, 1990).2.9. Statistical analyses
Analyses were performed with SPSS 19.0 (SPSS Inc, Chicago, IL,
USA) or SAS (version 9.3; SAS Institute Inc, Cary, NC, USA). Outliers
were kept in the analysis. Levene test was applied to test homo-
geneity of variances and Shapiro-Wilk test to test normal distri-
bution. If Shapiro-Wilk test was signiﬁcant, parametric testing was
still considered appropriate if the skewness value was between 1
and þ1. Chi-square tests were applied to test for the association
between categorical variables. Spearman rank correlation was used
to test for correlations. A correlation (rho) was considered weak
between 0.1 to 0.35, moderate between 0.36 and 0.65, and strong
>0.66 (the corresponding negative values were used for negative
correlations), and t tests or their respective nonparametric equiv-
alent (Mann-Whitney U test) were used for group comparisons.
Alpha error rate was controlled using the Bonferroni-Holm method
(Holm,1979). Repeated-measures analysis of variance (ANOVA)was
used to examine between-subject effects (MCI/HCS: PiB positive/
PiB negative and ApoE4 carriers vs. noncarriers). For group com-
parisons of >2 groups, ANOVA was followed by Fisher least sig-
niﬁcance difference test with Bonferroni correction for planned
comparisons. We conducted 2 subsets of analyses. One focused on
the comparison of PiB-positive versus PiB-negative subjects and
ApoE4 carriers versus noncarriers, which reﬂects the biological
aspect of cerebral amyloid deposition. The other subset focused on
the comparison between MCI and HCS that reﬂects the clinical
aspect of cognitively healthy versus cognitively impaired. For group
comparisons, effect sizes were calculated according to d ¼ m2m1SD pooled,
where standard deviation (SD) pooled was calculated according to
SD pooled ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðn21ÞSD22þðn11ÞSD12
n1þn22
r
with m2, n2, and SD2 repre-
senting mean, sample size, and SD of MCI and m1, n1, and SD1 for
HCS. Bias correction was included as follows:
dunbiased ¼ d1 34ðn1þn22Þ1

. A 95% CI for effect size was
calculated as follows: lower limit¼ d 1.96 standard error (SE) of
d; upper limit ¼ d þ 1.96  SE of d. The SE of d was calculated ac-
cording to dSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1þn2
n1n2
þ d22ðn1þn22Þ
q
. For calculation of effect sizes,
see also formulae 1, 2,14,15, and 17 in Nakagawa and Cuthill (2007).
Table 1
Sample description
n Age MMSE Education ApoE4 carrier
Total 108 69.2 (6.2) 29.2 (1.2) 15 (2.8) 33 (31%)a
HCS/MCI 85/23 68.3 (5.7)/72.3(7.3) 29.5 (0.8)/28.1 (2.0) 15.1 (2.7)/15.0 (2.9) 23/10
PiB positive 21 (19%) 73.1 (6.2) 28.2 (2.1) 14.1 (2.3) 16 (80%)a
HCS/MCI 11/10 72.1 (5.7)/74.2 (6.8) 29.5 (0.8)/26.8 (2.2) 14.6 (2.4)/13.4 (2.2) 7/9
PiB negative 87 (81%) 68.2 (5.9) 29.4 (0.8) 15.3 (2.8) 17 (20%)a
HCS/MCI 74/13 67.7 (5.5)/70.9 (7.5) 29.5 (0.7)/29.2 (1.1) 15.1 (2.8)/16.2 (2.9) 16/1
Mean and standard deviation (in brackets) are provided for age, MMSE, and education.
Key: ApoE4, apolipoprotein E ε4; HCS, healthy elderly control subjects; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PiB, [11C]-Pittsburgh
Compound B.
a Data on ApoE genotype were missing for 1 PiB-positive and 1 PiB-negative HCS.
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3.1. Sample description
A histogram of cortical PiB retention for the entire sample is
presented in Supplementary Fig. 1. EPiB data were available for 108
subjects who were considered for the subsequent analyses. PiB-
positive subjects were older than PiB-negative subjects (t ¼ 3.4,
degrees of freedom [df] ¼ 106, p < 0.001) and scored lower on the
MMSE (U ¼ 560.5, p ¼ 0.003). MCI were older than HCS (t ¼ 2.9,
df ¼ 106, p ¼ 0.005) and scored lower on the MMSE (U ¼ 537, p <
0.001). Table 1 provides the sample description. ApoE4-carrier
status was associated with PiB status (c2 ¼ 27.5, p < 0.001, phi ¼
0.51) but not with diagnosis. The odds ratio for an ApoE4 carrier to
be PiB positive was 16 (95% CI¼ 5e55) compared with a noncarrier.
Left and right TRs (rho ¼ 0.94, p < 0.001) and left and right SPG
(rho ¼ 0.93, p < 0.001) were strongly correlated and, therefore,
averaged to provide a bilateral measure (bilateral SPG and bilateral
TR). All other regions were considered separately.
3.2. Inﬂuence of amyloid deposition and ApoE4-carrier status on
ePiB
Levene test was signiﬁcant in the left IFG in the right and left
hipp and in the TR. Variances (max ¼ 0.005) and variance differ-
ences (max¼ 0.002) were small.We considered repeated-measures
ANOVA still appropriate to test the hypothesis that ePiB signal
measured in different regions (within-subject factor) demonstrates
a mean difference between PiB-positive and -negative subjects
(between-subject factor). No differences between PiB-positive and
-negative subjects were found (p ¼ 0.93). Repeated-measures
ANOVA to test for a mean difference between ApoE4 carriers and
noncarriers was also not signiﬁcant (p ¼ 0.45).
Scatterplots of PiB retention and ePiB (Supplementary Fig. 2) did
not show a monotonic relationship. This precluded Spearman rank
correlation for the entire sample; so, we computed correlations in
PiB-positive and -negative subjects separately. No regional associ-
ation was observed in PiB-positive subjects; however, a moderate
positive association was found in the PiB-negative subjects in the
bilateral SPG (rho ¼ 0.6, p < 0.001).
3.3. Effects of region volume and age on ePiB
The gray-matter VOIs in MNI space and ePiB signal were weak to
moderately correlated to ePiB (all adjusted p values < 0.01) in all
regions except the left and right parahipp. In the entire sample, there
was a signiﬁcant negative correlation of ePiB with age in the left hipp
(rho ¼ 0.3). When PiB-positive individuals were considered sepa-
rately, signiﬁcant correlations were found in the bilateral SPG,
bilateral TR, right PCC, left parahipp, and right IFG. Scatterplots of
ePiB and age for these regions are provided in Fig. 1. In all otherregions, we observed a negative correlation (see Table 2), which was
not signiﬁcant after p-value adjustment. In PiB-negative individuals,
no association of ePiB and age was observed. Table 2 reports the
associations of ePiB with age for the entire sample and for the PiB-
positive and -negative subgroups. In a next step, we examined the
association of ePiB with age in ApoE4 carriers and noncarriers
separately. No signiﬁcant difference was found.
3.4. ePiB in MCI versus HCS
Repeated-measures ANOVA was designed to test if ePiB
measured in different regions demonstrates a mean difference
between MCI and HCS. The assumption of sphericity was violated
(Mauchly test of sphericity: f ¼ 391, p < 0.001); therefore, a
Greenhouse-Geisser correction was applied ( 3¼ 0.518). A signiﬁ-
cant difference was observed in ePiB for the different regions
(within-subject effects) (df ¼ 4.66, F ¼ 999, p < 0.001). There was
an interaction between region and diagnosis (df ¼ 4.66, F ¼ 3.63,
p ¼ 0.004) and a signiﬁcant mean reduction in ePiB in MCI
compared with HCS (between-subject effects) (df ¼ 1, F ¼ 7.33, p ¼
0.008). Regions with signiﬁcant lower ePiB (p values surviving
Bonferroni-Holm correction for 10 comparisons) included the left
PCC (d ¼ 0.8, 95% CI ¼ 1.3 to 0.3, p < 0.001), left hipp
(d ¼ 0.8, 95% CI ¼ 1.3 to 0.3, p < 0.001), right (d ¼ 0.9, 95%
CI ¼ 1.4 to 0.4, p ¼ 0.004) hipp, and left IFG (d ¼ 0.8, 95%
CI ¼ 1.3 to 0.3, p < 0.001). To account for the potential inﬂu-
ence of age and PiB status on ePiB, we introduced an age split at 70
years and conducted a ﬁrst ANOVA which demonstrated that ePiB
differed between young HCS, young MCI, old HCS, and old MCI
(df ¼ 3, 104, p < 0.001 for left and right hipp, p < 0.01 for left IFG
and PCC). No signiﬁcant mean differences were found for planned
comparison between the young subjects. Planned comparison
between old HCS and old MCI revealed strong reductions in ePIB
in the all the regions as displayed on the boxplots in Fig. 2A. Effect
sizes and corrected p values (2 comparisons) were as follows: left
IFG (d ¼ 0.9, 95% CI ¼ 1.5 to 0.3, p ¼ 0.021), left PCC (d ¼ 1.0,
95% CI ¼ 1.7 to 0.4, p < 0.001), left hipp (d ¼ 1.2, 95%
CI ¼ 1.8 to 0.5, p < 0.001), and right hipp (d ¼ 1.4, 95%
CI ¼ 2.1 to 0.7, p < 0.001). In a second ANOVA to account for PiB
status, ePiB signal differed between young HCS, old HCS, young
PiB-positive MCI, young PiB-negative MCI, old PiB-positive MCI,
and old PiB-negative MCI (df ¼ 5, 102, p < 0.001 for left and right
hipp, p < 0.05 for left IFG and left PCC). The ﬁrst planned com-
parison old HCS versus old PiB-negative MCI demonstrated a
reduction in the right hipp for MCI (d ¼ 1.3, 95% CI ¼ 2.1
to 0.4) and the second planned comparison old HCS versus old
PiB-positive MCI identiﬁed lower ePiB in the left IFG (d ¼ 1.2,
95% CI ¼ 2.0 to 0.3, p ¼ 0.02), left PCC (d ¼ 1.2, 95% CI ¼ 2.1
to 0.4, p ¼ 0.002), left hipp (d ¼ 1.9, 95% CI ¼ 2.9 to 1, p <
0.001) and right hipp (d ¼ 1.7, 95% CI ¼ 2.6 to 0.8, p < 0.001).
These comparisons are displayed in Fig. 2B.
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Fig. 1. Scatterplots of age (x axis) and early uptake of [11C]-Pittsburgh Compound B (ePIB) (y axis). ePiB is inversely correlated with age in PiB-positive individuals (ﬁt line: long
dashes, red; mild cognitive impairment [MCI]: ﬁlled triangles, dark red; and HCS: ﬁlled circles, light red) not in PiB-negative individuals (ﬁt line: short dashes, blue; MCI: empty
triangles, blue; and HCS, empty circles, green). The black continuous line represents the ﬁt line for the entire sample.
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To our knowledge, this is the ﬁrst study to investigate ePiB signal
as an estimate of rCBF in a large number of subjects with MCI andTable 2
Correlation of ePiB with age
Left inf.
frontal
Right inf
frontal
Left PCC Right PCC Left
parahipp
All 0.25
p ¼ 0.010
0.23
p ¼ 0.019
0.14
p ¼ 0.142
0.03
p ¼ 0.759
0.02
p ¼ 0.804
PiB positive 0.46
p ¼ 0.038
L0.63
p[ 0.003*
0.35
p ¼ 0.124
L0.59
p [ 0.005*
L0.66
p [ 0.001
PiB negative 0.16
p ¼ 0.134
0.15
p ¼ 0.163
0.08
p ¼ 0.492
0.07
p ¼ 0.517
0.10
p ¼ 0.341
Spearman rho is provided for all regions, and p values are reported uncorrected. Signiﬁca
bold and with an asterisk.
Key: bilat, bilateral; ePiB, early uptake of [11C]-Pittsburgh Compound B; hipp, hippocam
sup, superior.HCS. We demonstrate a negative correlation of the rCBF estimate
ePiB with age in amyloid-positive individuals but not in amyloid-
negative individuals in regions relevant for AD. Furthermore, our
study is the ﬁrst to demonstrate that ePiB identiﬁes reduced rCBF inRight
parahipp
Left hipp Right hipp Bilat sup
parietal
Bilat
temporoparietal
0.09
p ¼ 0.370
L0.30
p[ 0.002*
0.22
p ¼ 0.021
0.09
p ¼ 0.372
0.19
p ¼ 0.056
*
0.47
p ¼ 0.033
0.50
p ¼ 0.021
0.49
p ¼ 0.025
L0.61
p [ 0.004*
L0.57
p [ 0.007*
0.02
p ¼ 0.837
0.22
p ¼ 0.044
0.18
p ¼ 0.101
0.01
p ¼ 0.898
0.10
p ¼ 0.375
nt associations after Bonferroni-Holm adjustment for 10 comparisons are marked in
pus; inf, inferior; parahipp, parahippocampal gyrus; PCC, posterior cingulate cortex;
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Fig. 2. (A) Boxplots of early uptake of [11C]-Pittsburgh Compound B (ePiB) signal (y axis) in regions showing signiﬁcant reductions in the mild cognitive impairment (MCI) of >70
years of age compared with the HCS of >70 years of age. The dashed red line represents the median of the entire sample. (B) Boxplots of ePiB signal (y axis) for HCS and MCI
including PiB status for MCI. The study subjects <70 years are depicted in dark blue and the study subjects >70 years in light green. The dashed line represents the median of the
entire sample.
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especially in those who also display elevated amyloid deposition.
4.1. The biological underpinnings of the ePiB signal
The biological relevance of the ePIB signal has been demon-
strated in studies that have revealed strong correlations with ce-
rebral glucose metabolism measured by FDG-PET (Forsberg et al.,
2012; Fu et al., 2014; Meyer et al., 2011; Rostomian et al., 2011).
However, the original concept of assessing ePiB signal is that it
estimates cortical blood ﬂow (Blomquist et al., 2008), which is
coupled to cerebral glucose metabolism (Paulson et al., 2010). Our
own data suggest that volume effects also contribute to ePiB signal
in the absence of partial volume correction; however, correlation
between volumes and ePiB signal was only weak to moderate. A
recent study found that ePiB only approximates CBF because of an
average extraction fraction of 0.53; however, relative changes in
cortical blood ﬂow between AD patients and controls and relative
changes of ePiB signal from the ﬁrst 1e5minutes correlated at an R2
of 0.99 (Gjedde et al., 2013).4.2. Association of age with ePiB as an estimate of rCBF in PiB-
positive subjects
In our study, we observed nomean differences in rCBF estimates
between PiB-positive and -negative subjects. ePiB was negatively
correlated with age in PiB-positive subjects but not in PiB-negative
subjects which is a new ﬁnding. An interaction of ApoE4 and age on
CBF has been described (Wierenga et al., 2013) that indirectly
supports our ﬁndings as ApoE4 is the strongest predictor of high
amyloid deposition in healthy subjects (Mielke et al., 2012), which
we also found in our sample. Hypermetabolism associated with
amyloid load has been demonstrated before in cognitively healthy
subjects (Oh et al., 2014). Interestingly, 2 studies including in-
dividuals from the Mayo Clinic Study of Aging have identiﬁed
reduced FDG signal in subjects with elevated amyloid deposition
(Knopman et al., 2014; Lowe et al., 2014) in regions wherewe found
the age amyloid-status interaction. Of note, in one of these studies,
the subjects for studying the association of metabolism and amy-
loid deposition were older than 70 years and the second included
subjects with a median age >77 years. This could be a potential
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interaction but no group differences between PiB-positive and
-negative subjects. Furthermore, we did also include subjects with
MCI in our analyses to encompass a broader spectrum of the aging
population. Several explanations may account for the association of
rCBF-estimate ePiB with age in PiB-positive individuals but not in
PiB-negative subjects. As suggested by the amyloid hypothesis of
AD (Hardy and Higgins, 1992) and the hypothetical model of dy-
namic biomarkers (Jack et al., 2010, 2013), we ﬁrst observe amyloid
accumulation which as the disease progresses will be accompanied
by synaptic loss and neurodegeneration with the consequence of
reduced rCBF. Furthermore, our observations are consistent with
the evidence of increased metabolism and CBF at some point in the
pathogenesis of AD that is later followed by a phase of reduced CBF
(Ostergaard et al., 2013; Thambisetty et al., 2010). Hypermetabo-
lism could be a compensatory mechanism (Elman et al., 2014)
(Mormino et al., 2012) or simply an indicator of aberrant neuronal
activity as a consequence of amyloid deposition (Kellner et al., 2014;
Sperling et al., 2009). Conversely, abberant neuronal activity could
promote amyloid deposition (Bero et al., 2011; Cirrito et al., 2005).
Important in this context is our ﬁnding of the positive association of
ePiB and late PiB signal in the superior parietal gyrus in PiB-
negative individuals. This could imply a pattern of low-levelamyloid deposition associated with higher rCBF that is disrupted in
subjects where high levels of amyloid deposition are reached.
Reductions in CBF with older age in PiB-positive subjects could
be caused by a decreasing vascular reserve (Brown and Thore, 2011)
or the inﬂuence of vascular amyloid deposition (cerebral amyloid
angiopathy) that has been implied by pathologic (Thal et al., 2008)
and imaging studies in humans (Chung et al., 2009; Peca et al.,
2013) and in animal studies (Merlini et al., 2011). A recent article
showed that transgenic APP23 mice that are prone to develop
plaques and cerebral amyloid angiopathy (Maier et al., 2014)
display a loss of cerebral perfusion with increasing age and disease
progression, whereas nontransgenic litter maids did not display any
change in rCBF. A second mouse model of AD (APPPS1), which is
usually devoid of CA, did not show changes in CBF at any age.
Translating this to our results suggests that pathologically deﬁned
cerebral amyloid angiopathy may contribute to the observed re-
ductions of CBF with age.
Another important aspect of our ﬁndings is that in amyloid-
negative subjects, we observe no changes between age and the
rCBF estimate. Previous studies on the association of CBF with age
have shown inconsistent results with some studies ﬁnding age-
associated decline (Aanerud et al., 2012; Leenders et al., 1990;
Marchal et al., 1992) and others not (Meltzer et al., 2000; Takada
A.F. Gietl et al. / Neurobiology of Aging 36 (2015) 1619e16281626et al., 1992). As AD becomes highly prevalent with increasing age, it
is difﬁcult to conduct these studies without including subjects that
already have evidence of AD (Jagust, 2013). We believe that our PiB-
negative subjects with preserved rCBF estimate represent an
important phenotype of healthy aging. The remaining question is
whether stable rCBF prevents amyloid deposition, which is sup-
ported by the fact that vascular risk factors also contribute to the
risk of AD (Akinyemi et al., 2013; Hasnain and Victor, 2014), or if
rCBF is preserved in the absence of strong amyloid deposition. The
ﬁrst possibility would strongly argue for therapeutic strategies
focusing on CBF in the prevention of AD.
4.3. Reduced ePiB in MCI compared with HCS
The regions that we studied were selected under the premise
that they were associated with MCI or predictive of cognitive
decline in FDG-PET studies as ePiB was linked to FDG-PET in the
previous studies (Forsberg et al., 2012; Fu et al., 2014; Meyer et al.,
2011; Rostomian et al., 2011). Similar to the FDG-PET studies, we
identiﬁed reduced rCBF estimates in the left and right hippocampus
(De Santi et al., 2001; Li et al., 2008; Mevel et al., 2007; Mosconi
et al., 2005; Nestor et al., 2003) and the PCC (Anchisi et al., 2005;
Drzezga et al., 2005; Landau et al., 2010; Nobili et al., 2008).
When CBF is assessed by ASL, reductions inMCI comparedwith HCS
were also detected in the left PCC, but in the hippocampus, also
increases of CBF have been reported (Alsop et al., 2010).
In our sample, no signiﬁcant reductions in ePiB were found in
either the superior parietal gyrus or TR where hypometabolismwas
described by FDG-PET (Anchisi et al., 2005; Arnaiz et al., 2001;
Chetelat et al., 2003; Drzezga et al., 2005; Landau et al., 2010;
Mosconi et al., 2004) and ASL literature (Alsop et al., 2010). This
may be because of the limited size of our MCI group. In a larger
multicentre cohort, hippocampal and PCC hypometabolism was
present in 81% of 114 MCI subjects, whereas additional lateral
temporal and inferior parietal hypometabolismwas only present in
25% of the cases and more frequent in subjects with multiple-
domain MCI (Mosconi et al., 2008). We also found a reduction in
ePiB in the left inferior frontal cortex. Evidence for the role of this
region in MCI/AD is not as abundant as for the regions discussed
earlier. A cluster with reduced glucose metabolism has been found
in inferior frontal structures when either stable MCI or MCI con-
verters after 1 year were compared with controls (Drzezga et al.,
2003). A cluster of hypometabolism in the left IFG was also found
in healthy subjects that have declined to MCI (de Leon et al., 2001).
ApoE4 carriers that converted from MCI to AD displayed lower
median metabolism in the left IFG compared with ApoE4 carriers
that did not convert or noncarriers (Mosconi et al., 2004). Our re-
sults provide additional evidence for impaired cerebral metabolism
or respectively blood ﬂow in the left IFG in MCI. We believe that
such an effect is plausible because of this region’s involvement in
semantic and phonological processing (Costafreda et al., 2006;
Katzev et al., 2013), in processes of empathy and working mem-
ory (Liakakis et al., 2011), and in tasks of self-awareness (Morin and
Michaud, 2007).
4.4. Contributions of age and amyloid status to the reduction of ePiB
in MCI
A recent ASL study identiﬁed rCBF reductions in AD regions
(among others, the hipp) when they compared AD subjects or PiB-
positive MCI with amyloid-negative controls but not when they
compared CBF in MCI with controls (not considering the amyloid
status) (Mattsson et al., 2014). Consistent with that, we found the
strongest reductions of ePiB in older MCI cases who are also PiB
positive. Therefore, individuals with 3 major risk factors forAlzheimer’s dementia, that is, age, amyloid deposition, and cogni-
tive impairment had the lowest estimates of rCBF. This implies a
potential for ePiB in identifying individuals at risk of Alzheimer’s
dementia.
4.5. Limitations
Our study has some limitations. We included no partial volume
correction; so, atrophy could have contributed to the effects of
reduced ePiB. We used different MRI scans for MCI and HCS. In MCI,
this could have resulted in higher ePiB signals. However, as we
observe an effect in the opposite direction, that is, lower ePiB inMCI
compared with HCS, we can be sure that this effect is not simply
caused by this methodological issue. Our data are cross sectional;
so, we cannot truly elaborate on the predictive value of ePiB for
cognitive decline. A limitation for interpreting the ﬁnding for the
association of age and ePiB in PiB-positive subjects is that the ePiB
signal is not an absolute measurement of cortical blood ﬂow. Also
the PiB-positive subjects were slightly older than the PiB-negative
subjects; so, we cannot entirely exclude the possibility that a fac-
tor independent of amyloid deposition becomes active on CBF with
higher age.
5. Conclusions
EPiB as an estimate for rCBF is associated with risk factors for
Alzheimer’s dementia. This warrants a longitudinal study on the
predictive value of ePiB in comparison with other easily accessible
biomarkers, for example, volumetric MR measures or ASL. Our
cross-sectional ﬁndings suggest an association of rCBF with age in
subjects with elevated amyloid deposition but not in subjects with
low-level amyloid deposition. This could mean that intact CBF in
the absence of amyloid deposition constitutes a phenotype of
healthy aging, whereas in the presence of amyloid deposition, a
reduction of CBF with age occurs in the context of AD.
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